Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;93(2):87-107.
doi: 10.1111/cod.14794. Epub 2025 Apr 2.

Contact Urticaria and Related Conditions: Clinical Review

Affiliations
Review

Contact Urticaria and Related Conditions: Clinical Review

Mojca Bizjak et al. Contact Dermatitis. 2025 Aug.

Abstract

Contact urticaria (CoU) is an immediate contact reaction occurring within minutes to an hour after exposure to specific proteins or chemicals. CoU is categorised into non-immunologic (NI-CoU) and immunologic (I-CoU) types, with I-CoU potentially leading to anaphylaxis. Both forms of CoU can be associated with protein contact dermatitis and the CoU syndrome. Patients with I-CoU may also have other type I (immediate) allergic diseases, such as allergic conjunctivitis, rhinitis, asthma or food allergy. This review provides a detailed overview of CoU and related conditions, focusing on triggers, diagnostic methods and management strategies. NI-CoU is typically triggered by low molecular weight chemicals, while I-CoU involves IgE-mediated hypersensitivity to both high molecular weight proteins and low molecular weight chemicals. Early diagnosis is crucial, though CoU is often underrecognized. The diagnostic approach includes a thorough medical history, physical examination, evaluation of photographs, (non)invasive skin tests and in vitro assessments. Management strategies prioritise trigger avoidance and pharmacological treatments when avoidance is not fully possible. For I-CoU, second-generation H1-antihistamines are the first-line treatment. Severe cases of I-CoU may benefit from anti-IgE therapy (omalizumab). Patients at risk of anaphylaxis should carry an adrenaline auto-injector and wear a medical alert bracelet.

Keywords: anaphylaxis; contact urticaria; inducible urticaria; occupational urticaria; protein contact dermatitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Gimenez‐Arnau A. M., Pesque D., and Maibach H. I., “Contact Urticaria Syndrome: A Comprehensive Review,” Current Dermatology Reports 11, no. 4 (2022): 194–201. - PMC - PubMed
    1. Magerl M., Altrichter S., Borzova E., et al., “The Definition, Diagnostic Testing, and Management of Chronic Inducible Urticarias—The EAACI/GA(2) LEN/EDF/UNEV Consensus Recommendations 2016 Update and Revision,” Allergy 71, no. 6 (2016): 780–802, 10.1111/all.12884. - DOI - PubMed
    1. Muraro A., Roberts G., Worm M., et al., “Anaphylaxis: Guidelines From the European Academy of Allergy and Clinical Immunology,” Allergy 69, no. 8 (2014): 1026–1045. - PubMed
    1. Anagnostou K. and Turner P. J., “Myths, Facts and Controversies in the Diagnosis and Management of Anaphylaxis,” Archives of Disease in Childhood 104, no. 1 (2019): 83–90. - PMC - PubMed
    1. Bizjak M., Rutkowski K., and Asero R., “Risk of Anaphylaxis Associated With Cold Urticaria,” Current Treatment Options in Allergy 11, no. 3 (2024): 167–175.

MeSH terms

Substances